Prescription drug pricing.
Do you support it?
Want to know if it passes?
We'll email you when SB 939 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on SB 939.
You're tracking SB 939
We'll email you the moment it moves.
SB 939 — Prescription drug pricing.
Last action — June 28 set for first hearing canceled at the request of author.
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
✓In Committee
-
3Passed Senate
-
4Passed Assembly
-
5To Executive
-
6Enacted
This bill died with 2021-2022 Regular Session. It reached “Passed Senate” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.
Summary
Existing federal law requires the United States Secretary of Health and Human Services to enter into an agreement with each manufacturer of covered outpatient drugs to ensure the amount a covered entity is required to pay for those drugs does not exceed the average manufacturer price of the drug under the federal Medicaid program. Existing state law requires a covered entity to dispense only drugs subject to these federal pricing requirements to Medi-Cal beneficiaries. Existing law defines a "covered entity" to include a federally qualified health center and entities receiving specified grants and federal funding. This bill would prohibit a pharmacy benefit manager from discriminating against a covered entity or its pharmacy in connection with dispensing a drug subject to federal pricing requirements or preventing a covered entity from retaining the benefit of discounted pricing for those drugs. The bill would prohibit a drug manufacturer that is subject to federal pricing requirements from imposing preconditions, limitations, delays, or other barriers to the purchase of covered drugs that are not required under federal law or regulations.
Bill Text
- Amended 06/15/22 - Amended Assembly Current pdf June 15, 2022
- Amended 03/15/22 - Amended Senate pdf March 15, 2022
- Introduced 02/08/22 - Introduced pdf February 08, 2022
- SB939 View text html
Action History
-
June 28 set for first hearing canceled at the request of author.
-
From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH.
-
Referred to Com. on HEALTH.
-
In Assembly. Read first time. Held at Desk.
-
Read third time. Passed. (Ayes 24. Noes 9. Page 3837.) Ordered to the Assembly.
-
Read second time. Ordered to third reading.
-
From committee: Do pass. (Ayes 9. Noes 1. Page 3203.) (March 23).
-
From committee with author's amendments. Read second time and amended. Re-referred to Com. on HEALTH.
-
Set for hearing March 23.
-
Referred to Com. on HEALTH.
-
From printer.
-
Article IV Section 8(a) of the Constitution and Joint Rule 55 dispensed with February 7, 2022, suspending the 30 calendar day requirement.
-
Introduced. Read first time. To Com. on RLS. for assignment. To print.
Sponsors
- Pan · Primary
- Scott D. Wiener · Cosponsor
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 1 co-sponsors · 120 not signed on · 4 voted No
Sponsors (1)
- Pan
Co-sponsors (1)
- Wiener, Scott D. Democratic
Not signed on (120)
120 members have not signed on to this bill.
Show all 120 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Votes
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 14 | 5 | 0 | 4 |
| Democratic | 10 | 0 | 0 | 3 |
| Republican | 0 | 4 | 0 | 0 |
| Total | 24 | 9 | 0 | 7 |
| % of votes cast | 60% | 23% | 0% | 18% |
How each member voted (40)
| Member | Party | Vote |
|---|---|---|
| Newman | — | Yea |
| Portantino | — | Yea |
| Leyva | — | Yea |
| Hueso | — | Yea |
| Gonzalez | — | Yea |
| Pan | — | Yea |
| Roth | — | Yea |
| Kamlager | — | Yea |
| Rubio | — | Yea |
| Wieckowski | — | Yea |
| Bradford | — | Yea |
| Skinner | — | Yea |
| Atkins | — | Yea |
| Eggman | — | Yea |
| Bates | — | Nay |
| Nielsen | — | Nay |
| Min | — | Nay |
| Wilk | — | Nay |
| Borgeas | — | Nay |
| Dodd | — | Not Voting |
| Melendez | — | Not Voting |
| Glazer | — | Not Voting |
| Hertzberg | — | Not Voting |
| Allen, Benjamin | Democratic | Yea |
| Archuleta, Bob | Democratic | Not Voting |
| Becker, Josh | Democratic | Not Voting |
| Caballero, Anna M. | Democratic | Not Voting |
| Cortese, Dave | Democratic | Yea |
| Durazo, Maria Elena | Democratic | Yea |
| Hurtado, Melissa | Democratic | Yea |
| Laird, John | Democratic | Yea |
| Limón, Monique | Democratic | Yea |
| McGuire, Mike | Democratic | Yea |
| Stern, Henry I. | Democratic | Yea |
| Umberg, Thomas J. | Democratic | Yea |
| Wiener, Scott D. | Democratic | Yea |
| Dahle, Megan | Republican | Nay |
| Grove, Shannon | Republican | Nay |
| Jones, Brian W. | Republican | Nay |
| Ochoa Bogh, Rosilicie | Republican | Nay |
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 6 | 0 | 0 | 1 |
| Democratic | 3 | 0 | 0 | 0 |
| Republican | 0 | 1 | 0 | 0 |
| Total | 9 | 1 | 0 | 1 |
| % of votes cast | 82% | 9% | 0% | 9% |
How each member voted (11)
| Member | Party | Vote |
|---|---|---|
| Gonzalez | — | Yea |
| Rubio | — | Yea |
| Roth | — | Yea |
| Pan | — | Yea |
| Leyva | — | Yea |
| Eggman | — | Yea |
| Melendez | — | Not Voting |
| Hurtado, Melissa | Democratic | Yea |
| Limón, Monique | Democratic | Yea |
| Wiener, Scott D. | Democratic | Yea |
| Grove, Shannon | Republican | Nay |
Subjects
Frequently asked questions
- What does SB 939 do?
- Existing federal law requires the United States Secretary of Health and Human Services to enter into an agreement with each manufacturer of covered outpatient drugs to ensure the amount a covered entity is required to pay for those drugs does not exceed the average manufacturer price of the drug under the federal Medicaid program. Existing state law requires a covered entity to dispense only drugs subject to these federal pricing requirements to Medi-Cal beneficiaries. Existing law defines a "covered entity" to include a federally qualified health center and entities receiving specified grants and federal funding. This bill would prohibit a pharmacy benefit manager from discriminating against a covered entity or its pharmacy in connection with dispensing a drug subject to federal pricing requirements or preventing a covered entity from retaining the benefit of discounted pricing for those drugs. The bill would prohibit a drug manufacturer that is subject to federal pricing requirements from imposing preconditions, limitations, delays, or other barriers to the purchase of covered drugs that are not required under federal law or regulations.
- Who sponsors SB 939?
- SB 939 is sponsored by Pan and Wiener, Scott D. (Democratic).
- What is the current status of SB 939?
- This bill died with 2021-2022 Regular Session. It reached “Passed Senate” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track SB 939?
- Track SB 939 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on SB 939
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of SB 939
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →